Niagen Bioscience Inc expected to post earnings of 2 cents a share - Earnings Preview

Niagen Bioscience

31/07/2026 22:11

Niagen Bioscience Inc NAGE.OQ NAGE.O is expected to  show a fall in quarterly revenue when it reports  results on August 4 for the period ending June 30 2026
The Los Angeles California-based  company is expected to report a 1.4% decrease in revenue to $30.69 million from $31.12 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Niagen Bioscience Inc is for earnings of 2 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Niagen Bioscience Inc is $11.00, about 231.3% above its last closing price of $3.32
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
0.07
0.07
0.07
Met
2.9
Dec. 31 2026
0.03
0.02
0.03
Beat
36.4
Sep. 30 2025
0.02
0.02
0.05
Beat
212.5​
Jun. 30 2025
0.02
0.01
0.04
Beat
185.7
​​Mar. 31 2025
0.02
0.02
0.06
Beat
166.7
Dec. 31 2024
0.02
0.02
0.09
Beat
350​
Sep. 30 2024
0.01
0.00
0.02
Beat
500.6
Jun. 30 2024
-0.02
-0.02
0.00
Beat
100
This summary was machine generated July 31 at 21:11 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)